{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:33:55Z","timestamp":1792704835695,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K09495"],"award-info":[{"award-number":["22K09495"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>When androgen receptor (AR) signaling is suppressed, prostate cancer progression is inhibited; however, many patients eventually relapse, developing castration-resistant prostate cancer (CRPC). Recently, the incidence of double-negative CRPC (DNPC)\u2014which lacks AR and neuroendocrine activity\u2014has increased, yet effective treatments remain unavailable. Our research demonstrated that KRAS has minimal influence during the AR-dependent stages of prostate cancer but significantly activates cancer cells when AR signaling is suppressed. Further investigation revealed that AR inhibition modifies fibroblast growth factor receptor expression in prostate cancer cells. Additionally, CCL2, secreted by AR-inhibited prostate cancer cells, induces FGF8b secretion from stromal cells within the tumor microenvironment, which in turn enhances KRAS activation. A pan-KRAS inhibitor effectively suppressed AR-independent prostate cancer cells by disrupting KRAS-mediated cell survival signaling. This inhibition led to the significant induction of programmed cell death, characterized by the downregulation of the anti-apoptotic protein BCL-xL and the promotion of apoptosis as evidenced by increased cleaved caspase-3 in vivo. These findings highlight KRAS activation, driven by the CRPC microenvironment, as a critical factor in DNPC progression and identify the induction of KRAS-targeted cell death as a promising therapeutic strategy for DNPC.<\/jats:p>","DOI":"10.1038\/s41419-026-08800-3","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:16:35Z","timestamp":1777695395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fibroblast-mediated KRAS activation in double-negative prostate cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2553-0497","authenticated-orcid":false,"given":"Taiki","family":"Kamijima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8480-9100","authenticated-orcid":false,"given":"Kouji","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Hiratsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Koketsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2503-8908","authenticated-orcid":false,"given":"Ryunosuke","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Toriumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Kadomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3599-2217","authenticated-orcid":false,"given":"Hiroaki","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yaegashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Shigehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Nakagawa-Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jye","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5643-2182","authenticated-orcid":false,"given":"Atsushi","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"8800_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"8800_CR2","first-page":"407","volume":"26","author":"G Jenster","year":"1999","unstructured":"Jenster G. The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol. 1999;26:407\u201321.","journal-title":"Semin Oncol"},{"key":"8800_CR3","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983\u201392.","journal-title":"Lancet Oncol"},{"key":"8800_CR4","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"8800_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360.","journal-title":"Lancet Oncol"},{"key":"8800_CR6","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378:1408\u201318.","journal-title":"N Engl J Med"},{"key":"8800_CR7","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","volume":"383","author":"K Fizazi","year":"2020","unstructured":"Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020;383:1040\u20139.","journal-title":"N Engl J Med"},{"key":"8800_CR8","doi-asserted-by":"crossref","unstructured":"Makino T, Izumi K, Mizokami A. Undesirable status of prostate cancer cells after intensive inhibition of AR signaling: post-AR era of CRPC treatment. Biomedicines. 2021;9:414.","DOI":"10.3390\/biomedicines9040414"},{"key":"8800_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/cncr.22372","volume":"109","author":"D Leibovici","year":"2007","unstructured":"Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitzhusen K, et al. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer. 2007;109:198\u2013204.","journal-title":"Cancer"},{"key":"8800_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-022-01267-z","volume":"15","author":"T Masuda","year":"2022","unstructured":"Masuda T, Kosaka T, Nakamura K, Hongo H, Yuge K, Nishihara H, et al. Multiple metastases of androgen indifferent prostate cancer in the urinary tract: two case reports and a literature review. BMC Med Genom. 2022;15:118.","journal-title":"BMC Med Genom"},{"key":"8800_CR11","first-page":"13","volume":"13","author":"H Jhaveri","year":"2017","unstructured":"Jhaveri H, Combs K, Jhaveri F. Direct extension of prostatic adenocarcinoma protruding through the urethral meatus. Urol Case Rep. 2017;13:13\u20135.","journal-title":"Urol Case Rep"},{"key":"8800_CR12","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","volume":"32","author":"EG Bluemn","year":"2017","unstructured":"Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell. 2017;32:474\u201389.e6.","journal-title":"Cancer Cell"},{"key":"8800_CR13","doi-asserted-by":"crossref","unstructured":"Zhang J, Chen Z, Mao Y, He Y, Wu X, Wu J, et al. ID2 promotes lineage transition of prostate cancer through FGFR and JAK-STAT signaling. Cancers (Basel). 2024;16:392.","DOI":"10.3390\/cancers16020392"},{"key":"8800_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45489-4","volume":"15","author":"WK Kim","year":"2024","unstructured":"Kim WK, Buckley AJ, Lee DH, Hiroto A, Nenninger CH, Olson AW, et al. Androgen deprivation induces double-null prostate cancer via aberrant nuclear export and ribosomal biogenesis through HGF and Wnt activation. Nat Commun. 2024;15:1231.","journal-title":"Nat Commun"},{"key":"8800_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ccell.2019.06.009","volume":"36","author":"W Su","year":"2019","unstructured":"Su W, Han HH, Wang Y, Zhang B, Zhou B, Cheng Y, et al. The polycomb repressor complex 1 drives double-negative prostate cancer metastasis by coordinating stemness and immune suppression. Cancer Cell. 2019;36:139\u201355.e10.","journal-title":"Cancer Cell"},{"key":"8800_CR16","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1002\/jcb.23291","volume":"112","author":"K Ishii","year":"2011","unstructured":"Ishii K, Mizokami A, Tsunoda T, Iguchi K, Kato M, Hori Y, et al. Heterogenous induction of carcinoma-associated fibroblast-like differentiation in normal human prostatic fibroblasts by co-culturing with prostate cancer cells. J Cell Biochem. 2011;112:3604\u201311.","journal-title":"J Cell Biochem"},{"key":"8800_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1442-2042.2007.01532.x","volume":"14","author":"Y Iwasa","year":"2007","unstructured":"Iwasa Y, Mizokami A, Miwa S, Koshida K, Namiki M. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP. Int J Urol. 2007;14:233\u20139.","journal-title":"Int J Urol"},{"key":"8800_CR18","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S0090-4295(97)00096-4","volume":"49","author":"D Krill","year":"1997","unstructured":"Krill D, Shuman M, Thompson MT, Becich MJ, Strom SC. A simple method for the isolation and culture of epithelial and stromal cells from benign and neoplastic prostates. Urology. 1997;49:981\u20138.","journal-title":"Urology"},{"key":"8800_CR19","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1677\/ERC-09-0070","volume":"16","author":"A Mizokami","year":"2009","unstructured":"Mizokami A, Koh E, Izumi K, Narimoto K, Takeda M, Honma S, et al. Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone. Endocr Relat Cancer. 2009;16:1139\u201355.","journal-title":"Endocr Relat Cancer"},{"key":"8800_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/2159-8274.CD-10-0022","volume":"1","author":"XS Wang","year":"2011","unstructured":"Wang XS, Shankar S, Dhanasekaran SM, Ateeq B, Sasaki AT, Jing X, et al. Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov. 2011;1:35\u201343.","journal-title":"Cancer Discov"},{"key":"8800_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/2159-8290.CD-20-0142","volume":"11","author":"MH Hofmann","year":"2021","unstructured":"Hofmann MH, Gmachl M, Ramharter J, Savarese F, Gerlach D, Marszalek JR, et al. BI-3406, a potent and selective SOS1\u2013KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. Cancer Discov. 2021;11:142\u201357.","journal-title":"Cancer Discov"},{"key":"8800_CR22","doi-asserted-by":"publisher","first-page":"15292","DOI":"10.1074\/jbc.271.25.15292","volume":"271","author":"DM Ornitz","year":"1996","unstructured":"Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem. 1996;271:15292\u20137.","journal-title":"J Biol Chem"},{"key":"8800_CR23","doi-asserted-by":"publisher","first-page":"15694","DOI":"10.1074\/jbc.M601252200","volume":"281","author":"X Zhang","year":"2006","unstructured":"Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem. 2006;281:15694\u2013700.","journal-title":"J Biol Chem"},{"key":"8800_CR24","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/emmm.201202367","volume":"5","author":"K Izumi","year":"2013","unstructured":"Izumi K, Fang LY, Mizokami A, Namiki M, Li L, Lin WJ, et al. Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2\/CCR2-induced STAT3 activation. EMBO Mol Med. 2013;5:1383\u2013401.","journal-title":"EMBO Mol Med"},{"key":"8800_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/cas.13876","volume":"110","author":"A Natsagdorj","year":"2019","unstructured":"Natsagdorj A, Izumi K, Hiratsuka K, Machioka K, Iwamoto H, Naito R, et al. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells. Cancer Sci. 2019;110:279\u201388.","journal-title":"Cancer Sci"},{"key":"8800_CR26","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.21873\/anticanres.16423","volume":"43","author":"A Natsagdorj","year":"2023","unstructured":"Natsagdorj A, Izumi K, Hiratsuka K, Naito R, Kadomoto S, Iwamoto H, et al. The CCL2\u2013CCR2 axis contributes to migration of cabazitaxel-resistant prostate cancer cells. Anticancer Res. 2023;43:2561\u20139.","journal-title":"Anticancer Res"},{"key":"8800_CR27","doi-asserted-by":"publisher","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","volume":"80","author":"H Sootome","year":"2020","unstructured":"Sootome H, Fujita H, Ito K, Ochiiwa H, Fujioka Y, Ito K, et al. Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res. 2020;80:4986\u201397.","journal-title":"Cancer Res"},{"key":"8800_CR28","doi-asserted-by":"publisher","first-page":"16737","DOI":"10.1021\/acs.jmedchem.4c01531","volume":"67","author":"RL Hudkins","year":"2024","unstructured":"Hudkins RL, Allen E, Balcer A, Hoffman ID, Iyer S, Neal M, et al. Discovery of TYRA-300: first oral selective FGFR3 inhibitor for the treatment of urothelial cancers and achondroplasia. J Med Chem. 2024;67:16737\u201356.","journal-title":"J Med Chem"},{"key":"8800_CR29","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a Multi-institutional Prospective Study. J Clin Oncol. 2018;36:2492\u2013503.","journal-title":"J Clin Oncol"},{"key":"8800_CR30","doi-asserted-by":"publisher","first-page":"358","DOI":"10.4111\/kju.2010.51.5.358","volume":"51","author":"DK Lee","year":"2010","unstructured":"Lee DK, Park JH, Kim JH, Lee SJ, Jo MK, Gil MC, et al. Progression of prostate cancer despite an extremely low serum level of prostate-specific antigen. Korean J Urol. 2010;51:358\u201361.","journal-title":"Korean J Urol"},{"key":"8800_CR31","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1146\/annurev.bi.56.070187.004023","volume":"56","author":"M Barbacid","year":"1987","unstructured":"Barbacid M. ras genes. Annu Rev Biochem. 1987;56:779\u2013827.","journal-title":"Annu Rev Biochem"},{"key":"8800_CR32","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","volume":"19","author":"SR Punekar","year":"2022","unstructured":"Punekar SR, Velcheti V, Neel BG, Wong KK. The current state of the art and future trends in RAS-targeted cancer therapies. Nat Rev Clin Oncol. 2022;19:637\u201355.","journal-title":"Nat Rev Clin Oncol"},{"key":"8800_CR33","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","volume":"30","author":"A Singhal","year":"2024","unstructured":"Singhal A, Li BT, O\u2019Reilly EM. Targeting KRAS in cancer. Nat Med. 2024;30:969\u201383.","journal-title":"Nat Med"},{"key":"8800_CR34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s13046-019-1374-x","volume":"38","author":"Q Yang","year":"2019","unstructured":"Yang Q, Lang C, Wu Z, Dai Y, He S, Guo W, et al. MAZ promotes prostate cancer bone metastasis through transcriptionally activating the KRas-dependent RalGEFs pathway. J Exp Clin Cancer Res. 2019;38:391.","journal-title":"J Exp Clin Cancer Res"},{"key":"8800_CR35","doi-asserted-by":"crossref","unstructured":"Masur J, Ratan A, Wierbilowicz K, Ayanambakkam A, Churchman ML, Graham LS, et al. Clinical and genomic features of androgen indifferent prostate cancer. Int J Mol Sci. 2025;26:679.","DOI":"10.3390\/ijms26020679"},{"key":"8800_CR36","first-page":"2053","volume":"58","author":"A Tanaka","year":"1998","unstructured":"Tanaka A, Furuya A, Yamasaki M, Hanai N, Kuriki K, Kamiakito T, et al. High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8. Cancer Res. 1998;58:2053\u20136.","journal-title":"Cancer Res"},{"key":"8800_CR37","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1038\/sj.onc.1202624","volume":"18","author":"TJ Dorkin","year":"1999","unstructured":"Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene. 1999;18:2755\u201361.","journal-title":"Oncogene"},{"key":"8800_CR38","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/sj.bjc.6600875","volume":"88","author":"VJ Gnanapragasam","year":"2003","unstructured":"Gnanapragasam VJ, Robinson MC, Marsh C, Robson CN, Hamdy FC, Leung HY. FGF8 isoform b expression in human prostate cancer. Br J Cancer. 2003;88:1432\u20138.","journal-title":"Br J Cancer"},{"key":"8800_CR39","first-page":"5369","volume":"57","author":"S Feng","year":"1997","unstructured":"Feng S, Wang F, Matsubara A, Kan M, McKeehan WL. Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res. 1997;57:5369\u201378.","journal-title":"Cancer Res"},{"key":"8800_CR40","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/path.2657","volume":"220","author":"T Murphy","year":"2010","unstructured":"Murphy T, Darby S, Mathers ME, Gnanapragasam VJ. Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype. J Pathol. 2010;220:452\u201360.","journal-title":"J Pathol"},{"key":"8800_CR41","doi-asserted-by":"publisher","first-page":"205","DOI":"10.12659\/MSM.891193","volume":"21","author":"X Wang","year":"2015","unstructured":"Wang X, Wen J, Li R, Qiu G, Zhou L, Wen X. Gene expression profiling analysis of castration-resistant prostate cancer. Med Sci Monit. 2015;21:205\u201312.","journal-title":"Med Sci Monit"},{"key":"8800_CR42","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1074\/jbc.272.6.3733","volume":"272","author":"AG Blunt","year":"1997","unstructured":"Blunt AG, Lawshe A, Cunningham ML, Seto ML, Ornitz DM, MacArthur CA. Overlapping expression and redundant activation of mesenchymal fibroblast growth factor (FGF) receptors by alternatively spliced FGF-8 ligands. J Biol Chem. 1997;272:3733\u20138.","journal-title":"J Biol Chem"},{"key":"8800_CR43","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/pros.24630","volume":"84","author":"MP Labrecque","year":"2024","unstructured":"Labrecque MP, Brown LG, Coleman IM, Nguyen HM, Dalrymple S, Brennen WN, et al. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer. Prostate. 2024;84:100\u201310.","journal-title":"Prostate"},{"key":"8800_CR44","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s10555-025-10272-4","volume":"44","author":"B Alsaed","year":"2025","unstructured":"Alsaed B, Bobik N, Laitinen H, Nandikonda T, Ilonen I, Haikala HM. Shaping the battlefield: EGFR and KRAS tumor mutations\u2019 role on the immune microenvironment and immunotherapy responses in lung cancer. Cancer Metastasis Rev. 2025;44:56.","journal-title":"Cancer Metastasis Rev"},{"key":"8800_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-025-02729-7","volume":"30","author":"W He","year":"2025","unstructured":"He W, Li H, Sun W, Zhang Y, Wu D, Ao C, et al. B7-H3 and c-MET in advanced prostate cancer: exploring possibilities of novel bi-specific drug development. Eur J Med Res. 2025;30:467.","journal-title":"Eur J Med Res"},{"key":"8800_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11033-025-11202-x","volume":"53","author":"AG Mukherjee","year":"2025","unstructured":"Mukherjee AG, Gopalakrishnan AV. HER2 as a molecular Trojan horse in prostate cancer: mechanistic insights and therapeutic unlocks. Mol Biol Rep. 2025;53:31.","journal-title":"Mol Biol Rep"},{"key":"8800_CR47","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRAS(G12C) inhibition with Sotorasib in advanced solid tumors. N Engl J Med. 2020;383:1207\u201317.","journal-title":"N Engl J Med"},{"key":"8800_CR48","first-page":"1337","volume":"52","author":"H Iwamoto","year":"2022","unstructured":"Iwamoto H, Izumi K, Nakagawa R, Toriumi R, Aoyama S, Shimada T, et al. Usefulness of serum CCL2 as prognostic biomarker in prostate cancer: a long-term follow-up study. Jpn J Clin Oncol. 2022;52:1337\u201344.","journal-title":"Jpn J Clin Oncol"},{"key":"8800_CR49","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/cas.15683","volume":"114","author":"H Kano","year":"2023","unstructured":"Kano H, Izumi K, Hiratsuka K, Toriumi R, Nakagawa R, Aoyama S, et al. Suppression of androgen receptor signaling induces prostate cancer migration via activation of the CCL20\u2013CCR6 axis. Cancer Sci. 2023;114:1479\u201390.","journal-title":"Cancer Sci"},{"key":"8800_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.270","volume":"4","author":"TH Lin","year":"2013","unstructured":"Lin TH, Izumi K, Lee SO, Lin WJ, Yeh S, Chang C. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis. 2013;4:e764.","journal-title":"Cell Death Dis"},{"key":"8800_CR51","doi-asserted-by":"publisher","first-page":"9739","DOI":"10.18632\/oncotarget.14185","volume":"8","author":"A Maolake","year":"2017","unstructured":"Maolake A, Izumi K, Shigehara K, Natsagdorj A, Iwamoto H, Kadomoto S, et al. Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22\u2013CCR4 axis. Oncotarget. 2017;8:9739\u201351.","journal-title":"Oncotarget"},{"key":"8800_CR52","first-page":"6116","volume":"63","author":"T Shimokawa","year":"2003","unstructured":"Shimokawa T, Furukawa Y, Sakai M, Li M, Miwa N, Lin YM, et al. Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the beta-catenin\/T-cell factor complex. Cancer Res. 2003;63:6116\u201320.","journal-title":"Cancer Res"},{"key":"8800_CR53","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1038\/s41388-017-0017-y","volume":"37","author":"P Guo","year":"2018","unstructured":"Guo P, Wang Y, Dai C, Tao C, Wu F, Xie X, et al. Ribosomal protein S15a promotes tumor angiogenesis via enhancing Wnt\/beta-catenin-induced FGF18 expression in hepatocellular carcinoma. Oncogene. 2018;37:1220\u201336.","journal-title":"Oncogene"},{"key":"8800_CR54","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1159\/000493286","volume":"49","author":"N Song","year":"2018","unstructured":"Song N, Zhong J, Hu Q, Gu T, Yang B, Zhang J, et al. FGF18 enhances migration and the epithelial\u2013mesenchymal transition in breast cancer by regulating Akt\/GSK3beta\/Beta-catenin signaling. Cell Physiol Biochem. 2018;49:1019\u201332.","journal-title":"Cell Physiol Biochem"},{"key":"8800_CR55","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13046-022-02266-9","volume":"41","author":"K Guo","year":"2022","unstructured":"Guo K, Ma Z, Zhang Y, Han L, Shao C, Feng Y, et al. HDAC7 promotes NSCLC proliferation and metastasis via stabilization by deubiquitinase USP10 and activation of beta-catenin\u2013FGF18 pathway. J Exp Clin Cancer Res. 2022;41:91.","journal-title":"J Exp Clin Cancer Res"},{"key":"8800_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1124520","volume":"13","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Sun S, Ling T, Chen Y, Zhou R, You Q. The role of fibroblast growth factor 18 in cancers: functions and signaling pathways. Front Oncol. 2023;13:1124520.","journal-title":"Front Oncol"},{"key":"8800_CR57","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1158\/0008-5472.CAN-24-1254","volume":"85","author":"Y Cui","year":"2025","unstructured":"Cui Y, Chang Y, Ma X, Sun M, Huang Y, Yang F, et al. Ephrin A1 stimulates CCL2 secretion to facilitate premetastatic niche formation and promote gastric cancer liver metastasis. Cancer Res. 2025;85:263\u201376.","journal-title":"Cancer Res"},{"key":"8800_CR58","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3892\/etm.2022.11776","volume":"25","author":"Z Peng","year":"2023","unstructured":"Peng Z, Pang H, Wu H, Peng X, Tan Q, Lin S, et al. CCL2 promotes proliferation, migration and angiogenesis through the MAPK\/ERK1\/2\/MMP9, PI3K\/AKT, Wnt\/beta\u2011catenin signaling pathways in HUVECs. Exp Ther Med. 2023;25:77.","journal-title":"Exp Ther Med"},{"key":"8800_CR59","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","volume":"619","author":"D Kim","year":"2023","unstructured":"Kim D, Herdeis L, Rudolph D, Zhao Y, Bottcher J, Vides A, et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature. 2023;619:160\u20136.","journal-title":"Nature"},{"key":"8800_CR60","doi-asserted-by":"publisher","first-page":"9678","DOI":"10.1021\/acs.jmedchem.2c00741","volume":"65","author":"JM Ketcham","year":"2022","unstructured":"Ketcham JM, Haling J, Khare S, Bowcut V, Briere DM, Burns AC, et al. Design and discovery of MRTX0902, a potent, selective, brain-penetrant, and orally bioavailable inhibitor of the SOS1:KRAS protein\u2013protein interaction. J Med Chem. 2022;65:9678\u201390.","journal-title":"J Med Chem"},{"key":"8800_CR61","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","volume":"14","author":"J Jiang","year":"2024","unstructured":"Jiang J, Jiang L, Maldonato BJ, Wang Y, Holderfield M, Aronchik I, et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov. 2024;14:994\u20131017.","journal-title":"Cancer Discov"},{"key":"8800_CR62","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","volume":"629","author":"M Holderfield","year":"2024","unstructured":"Holderfield M, Lee BJ, Jiang J, Tomlinson A, Seamon KJ, Mira A, et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature. 2024;629:919\u201326.","journal-title":"Nature"},{"key":"8800_CR63","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1007\/s10637-012-9869-8","volume":"31","author":"KJ Pienta","year":"2013","unstructured":"Pienta KJ, Machiels JP, Schrijvers D, Alekseev B, Shkolnik M, Crabb SJ, et al. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs. 2013;31:760\u20138.","journal-title":"Invest New Drugs"},{"key":"8800_CR64","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.2174\/156802610791561255","volume":"10","author":"M Struthers","year":"2010","unstructured":"Struthers M, Pasternak A. CCR2 antagonists. Curr Top Med Chem. 2010;10:1278\u201398.","journal-title":"Curr Top Med Chem"},{"key":"8800_CR65","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.canlet.2021.11.030","volume":"526","author":"P Chiodelli","year":"2022","unstructured":"Chiodelli P, Coltrini D, Turati M, Cerasuolo M, Maccarinelli F, Rezzola S, et al. FGFR blockade by pemigatinib treats naive and castration resistant prostate cancer. Cancer Lett. 2022;526:217\u201324.","journal-title":"Cancer Lett"},{"key":"8800_CR66","doi-asserted-by":"crossref","unstructured":"Pungsrinont T, Kallenbach J, Baniahmad A. Role of PI3K\u2013AKT\u2013mTOR pathway as a pro-survival signaling and resistance-mediating mechanism to therapy of prostate cancer. Int J Mol Sci. 2021;22:11088.","DOI":"10.3390\/ijms222011088"},{"key":"8800_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114103","volume":"205","author":"P Rescigno","year":"2024","unstructured":"Rescigno P, Porta N, Finneran L, Riisnaes R, Figueiredo I, Carreira S, et al. Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: results from the randomized phase II RE-AKT trial. Eur J Cancer. 2024;205:114103.","journal-title":"Eur J Cancer"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08800-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08800-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08800-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:03:19Z","timestamp":1777942999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08800-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8800"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08800-3","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Medical Ethics Committee of Kanazawa University (Approval numbers: 2019-012, 2020-286). Written informed consent was obtained from all patients. Mouse care and treatment were approved by the Institutional Animal Care and Use Committee of the Graduate School of Medical Science, Kanazawa University (Approval number: AP-214247). All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"ETHICS APPROVAL"}}],"article-number":"403"}}